MAINZ BIOMED N.V. — Form D/A
MAINZ BIOMED N.V. of MAINZ, 2M, a company, filed a Form D amendment with the SEC on 2024-05-10. The offering totals $50.0M, of which $14.3M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-05-10
- Form: D/A
- Accession: 0001213900-24-041832
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $50.0M
- Amount sold: $14.3M
- Remaining: $35.7M
- Investors: 1
- Date of first sale: 2023-06-28
- Security types: equity, debt
- Revenue range: Decline to Disclose
- SEC file number: 021-486514
Issuer
- Name: MAINZ BIOMED N.V.
- CIK: 0001874252
- Entity type: Corporation
- Jurisdiction: NETHERLANDS
- Incorporated: 2021
- Address: ROBERT KOCH STRASSE 50, MAINZ, 2M, 55129
- Phone: +49-6131-55428-60
Officers, directors & promoters (13)
| Name | Role | Location |
|---|
| Guido Baechler | Director | Toronto, A6 |
| Heiner Dreismann | Director | EXTON, PA |
| Moritz Eidens | Director | Mainz, 2M |
| Hans Hekland | Director | Mainz, 2M |
| Nicole Holden | Director | Mainz, 2M |
| Alberto Libanori | Director | Mainz, 2M |
| Gregory Tibbits | Director | Mainz, 2M |
| Guido Baechler | Executive Officer | Toronto, A6 |
| William Caragol | Executive Officer | Boca Raton, FL |
| Moritz Eidens | Executive Officer | Mainz, 2M |
| Phillip Freese | Executive Officer | Mainz, 2M |
| Darin Leigh | Executive Officer | Mainz, 2M |
| Marco Messina | Director | Mainz, 2M |
Other filings by this issuer (2)
More